文献速递血栓与止血

癌症相关静脉血栓栓塞症的危险因素:VTE-PACC研究

Risk factors for cancer-associated venous thromboembolism: The venous thromboembolism prevention in the ambulatory cancer clinic (VTE-PACC) study.
PubMed 文献 · J Thromb Haemost · 2019-09-22

VTE-PACC研究在单中心2012-14年纳入1583例开始化疗的患者,评估癌症相关静脉血栓栓塞症(CAT)的危险因素。6个月分析中未发现Khorana评分以外的额外危险因素;3年分析中男性、既往VTE和住院与CAT风险升高相关。

要点

  • 6个月CAT分析中,未发现Khorana评分之外的额外危险因素。
  • 3年分析中,男性、既往VTE和住院与CAT风险升高相关。
  • 将住院作为时变协变量纳入风险评估具有重要性。

核心结论

  • 将时间-事件数据纳入CAT风险评估时,男性、既往VTE和住院是重要危险因素。
  • 这些数据强调需要考虑动态方法评估癌症患者的VTE风险,尤其关注住院前后时期。

研究设计与样本

  • 单中心研究,纳入2012-14年开始化疗的患者,记录危险因素。
  • 住院及住院后时间段作为时变协变量评估。
  • 采用逻辑回归分析6个月CAT风险(Khorana评分终点),采用比例风险模型识别3年观察期内的危险因素。

主要发现

  • 共纳入1583例开始化疗的患者(平均年龄60岁,48%男性),187例发生CAT(11.8%),其中129例(69%)发生在开始化疗后6个月内。
  • 6个月分析中,未发现与CAT相关的额外危险因素。
  • 3年分析中,校正Khorana评分中的危险因素后,男性(HR 1.57,95%CI 1.21,2.07)、既往VTE(HR 2.12,95%CI 1.41,3.18)和住院(HR 2.69,95%CI 1.92,3.75)与CAT风险升高相关。

临床怎么用

  • 在癌症患者VTE风险评估中,可考虑纳入男性、既往VTE和住院等动态因素。
  • 特别关注住院前后时期的VTE风险。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Khorana Score is a validated risk score for predicting 6-month incidence of cancer-associated venous thromboembolism (CAT) among patients starting chemotherapy. Venous thromboembolism (VTE) risk factors important in the general population, including age, sex, prior VTE, and hospitalization, are not included in this score, their association with VTE in cancer patients is unknown. OBJECTIVE: To examine risk factors for CAT and the impact of incorporating longitudinal hospitalization into risk assessment. METHODS: Risk factors were recorded among patients starting chemotherapy at a single institution from 2012-14. Hospitalization and time-periods after hospitalization were assessed as time-varying covariates. Logistic regression was used to determine factors related to 6-month CAT risk (the Khorana Score endpoint). Proportional hazard models were used for risk factor identification throughout the 3-year observation period. RESULTS: Among 1,583 patients starting chemotherapy (mean age 60, 48% male), 187 developed CAT (11.8%) with 129 (69%) cases occurring within 6 months of starting chemotherapy. In the 6-month analysis, no additional risk factors were associated with CAT. In the 3-year analysis, male sex (HR 1.57, 95%CI 1.21, 2.07), prior VTE (HR 2.12, 95%CI 1.41, 3.18), and hospitalization (HR 2.69, 95%CI 1.92, 3.75) were associated with increased hazard of CAT, adjusting for risk factors in the Khorana score. CONCLUSIONS: When time-to-event data were incorporated into CAT risk assessment, male sex, prior VTE, and hospitalization were important risk factors. These data highlight the need to consider dynamic methods for assessing VTE risk in cancer patients, with particular attention to the period around hospitalizations.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Douce DR, Holmes CE, Cushman M, et al. Risk factors for cancer-associated venous thromboembolism: The venous thromboembolism prevention in the ambulatory cancer clinic (VTE-PACC) study. J Thromb Haemost. 2019. PMID: 31423717. doi:10.1111/jth.14614

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。